Elena Zafarana

Carboplatin-based doublet plus bevacizumab beyond progression versus carboplatin-based doublet alone in patients with platinum-sensitive ovarian cancer: a randomised, phase 3 trial

Sandro Pignata, Domenica Lorusso, Florence Joly et al. · The Lancet Oncology · 2021 · 149 citations

Medicine, Gynecology, Oncology +15

Identification of a serum-detectable metabolomic fingerprint potentially correlated with the presence of micrometastatic disease in early breast cancer patients at varying risks of disease relapse by traditional prognostic methods

Catherine Oakman, Leonardo Tenori, Wederson M. Claudino et al. · Annals of Oncology · 2011 · 99 citations · Full text

Life Sciences, Biochemistry, Oncology +16

Estimating the risk of chemotherapy toxicity in older patients with cancer: The role of the Vulnerable Elders Survey-13 (VES-13)

Andrea Luciani, Laura Biganzoli, Giuseppe Colloca et al. · Journal of Geriatric Oncology · 2015 · 75 citations

Medicine, Geriatric Medicine, Oncology +16

Carboplatin and paclitaxel plus avelumab compared with carboplatin and paclitaxel in advanced or recurrent endometrial cancer (MITO END-3): a multicentre, open-label, randomised, controlled, phase 2 trial

Sandro Pignata, Vittoria Carbone, Eleonora Zaccarelli et al. · The Lancet Oncology · 2023 · 51 citations

Medicine, Oncology, Pharmacology +11

Evaluation of the cardiovascular health study (CHS) instrument and the Vulnerable Elders Survey-13 (VES-13) in elderly cancer patients. Are we still missing the right screening tool?

Laura Biganzoli, Luca Boni, Dimitri Becheri et al. · Annals of Oncology · 2012 · 34 citations · Full text

Medicine, Geriatric Medicine, Oncology +14